Oric Pharma Reports Strong Phase 1b Data for Two Lead Oncology Candidates, Extends Cash Runway into H2 2028

summarizeSummary

Oric Pharmaceuticals reported strong Phase 1b clinical data for rinzimetostat and enozertinib, with both candidates advancing towards Phase 3 trials, and secured funding to extend its cash runway into H2 2028, despite significant share dilution.

check_boxKey Events

• Rinzimetostat Advances to Phase 3

  The company completed Phase 1b dose exploration for rinzimetostat in mCRPC, reporting strong PSA (55% PSA50, 20% PSA90 confirmed) and ctDNA (76% >50% reduction, 59% clearance) responses. Phase 3 registrational trial initiation is expected in the first half of 2026.

• Enozertinib Shows Strong CNS Activity, Ready for Phase 3

  Enozertinib's Phase 1b data demonstrated highly competitive systemic and profound intracranial antitumor activity in EGFR exon 20 and PACC mutated NSCLC. The 80mg QD monotherapy dose has been selected for potential Phase 3 development.

• Extended Cash Runway into H2 2028

  Oric Pharmaceuticals reported $392.3 million in cash, cash equivalents, and investments as of December 31, 2025, projecting sufficient funds to support operations into the second half of 2028.

• Significant Capital Raises in 2025

  The company raised approximately $117.6 million net from ATM offerings and $124.4 million net from a private placement in 2025, leading to a substantial increase in shares outstanding (approximately 39%).

auto_awesomeAnalysis

Oric Pharmaceuticals' annual report highlights significant clinical advancements for its two lead oncology candidates, rinzimetostat and enozertinib, both showing promising Phase 1b data and progressing towards Phase 3 trials. Rinzimetostat demonstrated strong PSA and ctDNA responses in mCRPC, with Phase 3 initiation expected in the first half of 2026. Enozertinib achieved competitive systemic and profound CNS antitumor activity in NSCLC, with 80mg QD selected for potential Phase 3 monotherapy. These clinical successes are crucial for a clinical-stage biotech. The company has also extended its cash runway into the second half of 2028 through substantial capital raises in 2025, including a $117.6 million ATM offering and a $124.4 million net private placement, which resulted in significant share dilution (approximately 39% increase in shares outstanding). A strategic pipeline prioritization in August 2025, including a 20% workforce reduction, aims to focus resources on these lead programs. While the dilution is notable, the successful funding and clinical progress provide a solid foundation for future development.